TLR-7 and -8 agonists as vaccine adjuvants

References

• Singh M, Ugozzoli M, Kazzaz J et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine24(10), 1680–1686 (2006).
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol.6, 277–296 (1995).
   PubMedGoogle Scholar
• Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv. Drug Deliv. Rev.60(7), 813–823 (2008).
   PubMed Web of Science ®Google Scholar
• Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol.36(12), 3256–3267 (2006).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol.3(2), 196–200 (2002).
   PubMed Web of Science ®Google Scholar
• Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol.3(6), 499 (2002).
   PubMed Web of Science ®Google Scholar
• Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr. Mol. Med.3(4), 373–385 (2003).
   PubMed Web of Science ®Google Scholar
• Wysocka M, Newton S, Benoit BM et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-γ enhances production of interleukin-12. Clin. Lymphoma Myeloma7(8), 524–534 (2007).
   PubMedGoogle Scholar
• Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect.21(2), 69–87 (2008).
   PubMedGoogle Scholar
• Ahonen CL, Gibson SJ, Smith RM et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell. Immunol.197(1), 62–72 (1999).
   PubMed Web of Science ®Google Scholar
• Lore K, Betts MR, Brenchley JM et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol.171(8), 4320–4328 (2003).
   PubMed Web of Science ®Google Scholar
• Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-α/β. Immunol. Cell. Biol.82(6), 596–602 (2004).
   PubMed Web of Science ®Google Scholar
• Ma R, Du JL, Huang J, Wu CY. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem. Biophys. Res. Commun.361(2), 537–542 (2007).
   PubMed Web of Science ®Google Scholar
• Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol.204(1), 64–74 (2000).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol.174(12), 7676–7683 (2005).
   PubMed Web of Science ®Google Scholar
• Du J, Wu Z, Ren S et al. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine28(38), 6273–6281 (2010).
   PubMed Web of Science ®Google Scholar
• Otero M, Calarota SA, Felber B et al. Resiquimod is a modest adjuvant for HIV-1 Gag-based genetic immunization in a mouse model. Vaccine22(13–14), 1782–1790 (2004).
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine22(13–14), 1799–1809 (2004).
   PubMed Web of Science ®Google Scholar
• Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine23(45), 5263–5270 (2005).
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Doxsee CL, McGurran SM et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med.199(6), 775–784 (2004).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl Acad. Med. USA102(42), 15190–15194 (2005).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime–boost immunization in nonhuman primates. J. Exp. Med.203(5), 1249–1258 (2006).
   PubMed Web of Science ®Google Scholar